☰

Frank J. Slack - Publications

Affiliations: 
2000-2014 Molecular, Cellular and Developmental Biology Yale University, New Haven, CT 
 2014- Pathology Harvard Medical School, Boston, MA, United States 
Area:
Molecular Biology, Biochemistry
Website:
https://www.bidmc.org/research/research-by-department/pathology/laboratories/frank-slack-lab
Tree Info Similar researchers PubMed Report error

213 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2023 Naderi Yeganeh P, Teo YY, Karagkouni D, Pita-Juárez Y, Morgan SL, Slack FJ, Vlachos IS, Hide WA. PanomiR: a systems biology framework for analysis of multi-pathway targeting by miRNAs. Briefings in Bioinformatics. 24. PMID 37985452 DOI: 10.1093/bib/bbad418  0.445
2023 Li C, Yoon B, Stefani G, Slack FJ. Lipid kinase PIP5K1A regulates let-7 microRNA biogenesis through interacting with nuclear export protein XPO5. Nucleic Acids Research. PMID 37655623 DOI: 10.1093/nar/gkad709  0.455
2023 Kasina V, Wahane A, Liu CH, Yang L, Nieh MP, Slack FJ, Bahal R. Next-generation poly-L-histidine formulations for miRNA mimic delivery. Molecular Therapy. Methods & Clinical Development. 29: 271-283. PMID 37123088 DOI: 10.1016/j.omtm.2023.03.015  0.447
2023 Matai L, Slack FJ. MicroRNAs in Age-Related Proteostasis and Stress Responses. Non-Coding Rna. 9. PMID 37104008 DOI: 10.3390/ncrna9020026  0.382
2023 Matai L, Stathis T, Lee JD, Parsons C, Saxena T, Shlomchik K, Slack FJ. The conserved microRNA-229 family controls low-insulin signaling and dietary restriction induced longevity through interactions with SKN-1/NRF2. Aging Cell. e13785. PMID 36748780 DOI: 10.1111/acel.13785  0.343
2022 Dhuri K, Pradeep SP, Shi J, Anastasiadou E, Slack FJ, Gupta A, Zhong XB, Bahal R. Simultaneous Targeting of Multiple oncomiRs with Phosphorothioate or PNA-Based Anti-miRs in Lymphoma Cell Lines. Pharmaceutical Research. PMID 36071352 DOI: 10.1007/s11095-022-03383-y  0.511
2022 Zhang WC, Skiados N, Aftab F, Moreno C, Silva L, Corbilla PJA, Asara JM, Hata AN, Slack FJ. MicroRNA-21 guide and passenger strand regulation of adenylosuccinate lyase-mediated purine metabolism promotes transition to an EGFR-TKI-tolerant persister state. Cancer Gene Therapy. PMID 35840668 DOI: 10.1038/s41417-022-00504-y  0.378
2022 Baker AR, Miliotis C, Ramírez-Moya J, Marc T, Vlachos IS, Santisteban P, Slack FJ. Transcriptome profiling of ADAR1 targets in triple-negative breast cancer cells reveals mechanisms for regulating growth and invasion. Molecular Cancer Research : McR. PMID 35247916 DOI: 10.1158/1541-7786.MCR-21-0604  0.306
2021 Lee SM, Kaye KM, Slack FJ. Cellular microRNA-127-3p suppresses oncogenic herpesvirus-induced transformation and tumorigenesis via down-regulation of SKP2. Proceedings of the National Academy of Sciences of the United States of America. 118. PMID 34725152 DOI: 10.1073/pnas.2105428118  0.389
2021 Dhuri K, Gaddam RR, Vikram A, Slack FJ, Bahal R. Therapeutic potential of chemically modified, synthetic, triplex peptide nucleic acid-based oncomiR inhibitors for cancer therapy. Cancer Research. PMID 34548334 DOI: 10.1158/0008-5472.CAN-21-0736  0.35
2021 Peinado P, Andrades A, Martorell-Marugán J, Haswell JR, Slack FJ, Carmona-Sáez P, Medina PP. The SWI/SNF complex regulates the expression of miR-222, a tumor suppressor microRNA in lung adenocarcinoma. Human Molecular Genetics. PMID 34240140 DOI: 10.1093/hmg/ddab187  0.344
2021 Li WJ, Wang Y, Liu R, Kasinski AL, Shen H, Slack FJ, Tang DG. MicroRNA-34a: Potent Tumor Suppressor, Cancer Stem Cell Inhibitor, and Potential Anticancer Therapeutic. Frontiers in Cell and Developmental Biology. 9: 640587. PMID 33763422 DOI: 10.3389/fcell.2021.640587  0.332
2020 Anastasiadou E, Seto A, Beatty X, Hermreck M, Gilles ME, Stroopinsky D, Pinter-Brown LC, Pestano L, Marchese C, Avigan D, Trivedi P, Escolar D, Jackson A, Slack FJ. Cobomarsen, an oligonucleotide inhibitor of miR-155, slows DLBCL tumor cell growth and . Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 33208342 DOI: 10.1158/1078-0432.CCR-20-3139  0.31
2020 Malik S, Lim J, Slack FJ, Braddock DT, Bahal R. Next generation miRNA inhibition using short anti-seed PNAs encapsulated in PLGA nanoparticles. Journal of Controlled Release : Official Journal of the Controlled Release Society. PMID 32835710 DOI: 10.1016/J.Jconrel.2020.08.026  0.477
2020 Foster DJ, Chang HM, Haswell JR, Gregory RI, Slack FJ. TRIM71 binds to IMP1 and is capable of positive and negative regulation of target RNAs. Cell Cycle (Georgetown, Tex.). 1-13. PMID 32816599 DOI: 10.1080/15384101.2020.1804232  0.303
2020 Segal M, Slack FJ. Challenges identifying efficacious miRNA therapeutics for cancer. Expert Opinion On Drug Discovery. 1-5. PMID 32421364 DOI: 10.1080/17460441.2020.1765770  0.529
2020 Nagarajan MB, Tentori AM, Zhang WC, Slack FJ, Doyle PS. Spatially resolved and multiplexed MicroRNA quantification from tissue using nanoliter well arrays. Microsystems & Nanoengineering. 6: 51. PMID 32419951 DOI: 10.1038/S41378-020-0169-8  0.477
2020 Ramírez-Moya J, Baker AR, Slack FJ, Santisteban P. ADAR1-mediated RNA editing is a novel oncogenic process in thyroid cancer and regulates miR-200 activity. Oncogene. PMID 32157211 DOI: 10.1038/S41388-020-1248-X  0.462
2020 Rupaimoole R, Yoon B, Zhang WC, Adams BD, Slack FJ. A High-Throughput Small Molecule Screen Identifies Ouabain as Synergistic with miR-34a in Killing Lung Cancer Cells. Iscience. 23: 100878. PMID 32062455 DOI: 10.1016/J.Isci.2020.100878  0.419
2019 Segal M, Biscans A, Gilles ME, Anastasiadou E, De Luca R, Lim J, Khvorova A, Slack FJ. Hydrophobically Modified let-7b miRNA Enhances Biodistribution to NSCLC and Downregulates HMGA2 In Vivo. Molecular Therapy. Nucleic Acids. 19: 267-277. PMID 31855835 DOI: 10.1016/J.Omtn.2019.11.008  0.564
2019 Slack FJ, Chinnaiyan AM. The Role of Non-coding RNAs in Oncology. Cell. 179: 1033-1055. PMID 31730848 DOI: 10.1016/J.Cell.2019.10.017  0.346
2019 Witten L, Slack FJ. miR-155 as a novel clinical target for hematological malignancies. Carcinogenesis. PMID 31711135 DOI: 10.1093/Carcin/Bgz183  0.546
2019 Mavrikaki M, Pantano L, Potter D, Rogers-Grazado MA, Anastasiadou E, Slack FJ, Amr SS, Ressler KJ, Daskalakis NP, Chartoff E. Sex-Dependent Changes in miRNA Expression in the Bed Nucleus of the Stria Terminalis Following Stress. Frontiers in Molecular Neuroscience. 12: 236. PMID 31636537 DOI: 10.3389/Fnmol.2019.00236  0.456
2019 Zhang WC, Wells JM, Chow KH, Huang H, Yuan M, Saxena T, Melnick MA, Politi K, Asara JM, Costa DB, Bult CJ, Slack FJ. miR-147b-mediated TCA cycle dysfunction and pseudohypoxia initiate drug tolerance to EGFR inhibitors in lung adenocarcinoma. Nature Metabolism. 1: 460-474. PMID 31535082 DOI: 10.1038/s42255-019-0052-9  0.326
2019 Gilles ME, Hao L, Brown K, Lim J, Bhatia SN, Slack FJ. Tumor penetrating nanomedicine targeting both an oncomiR and an oncogene in pancreatic cancer. Oncotarget. 10: 5349-5358. PMID 31523393 DOI: 10.18632/Oncotarget.27160  0.452
2019 Mavrikaki M, Anastasiadou E, Ozdemir RA, Potter D, Helmholz C, Slack FJ, Chartoff EH. Overexpression of miR-9 in the nucleus accumbens increases oxycodone self-administration. The International Journal of Neuropsychopharmacology. PMID 30989210 DOI: 10.1093/Ijnp/Pyz015  0.451
2018 Jiao AL, Perales R, Umbreit NT, Haswell JR, Piper ME, Adams BD, Pellman D, Kennedy S, Slack FJ. Human Nuclear RNAi-Defective 2 (NRDE2) is an essential RNA splicing factor. Rna (New York, N.Y.). PMID 30538148 DOI: 10.1261/Rna.069773.118  0.681
2018 Witten LW, Cheng CJ, Slack FJ. miR-155 drives oncogenesis by promoting and cooperating with mutations in the c-Kit oncogene. Oncogene. PMID 30459357 DOI: 10.1038/S41388-018-0571-Y  0.442
2018 Gilles ME, Slack FJ. Let-7 microRNA as a potential therapeutic target with implications for immunotherapy. Expert Opinion On Therapeutic Targets. 1-11. PMID 30328720 DOI: 10.1080/14728222.2018.1535594  0.547
2018 Choe J, Lin S, Zhang W, Liu Q, Wang L, Ramirez-Moya J, Du P, Kim W, Tang S, Sliz P, Santisteban P, George RE, Richards WG, Wong KK, Locker N, ... Slack FJ, et al. mRNA circularization by METTL3-eIF3h enhances translation and promotes oncogenesis. Nature. PMID 30232453 DOI: 10.1038/S41586-018-0538-8  0.361
2018 Nagarajan MB, Tentori AM, Zhang WC, Slack FJ, Doyle PS. Nonfouling, Encoded Hydrogel Microparticles for Multiplex MicroRNA Profiling Directly from Formalin-Fixed, Paraffin-Embedded Tissue. Analytical Chemistry. PMID 30106558 DOI: 10.1021/Acs.Analchem.8B02010  0.49
2018 Anastasiadou E, Faggioni A, Trivedi P, Slack FJ. The Nefarious Nexus of Noncoding RNAs in Cancer. International Journal of Molecular Sciences. 19. PMID 30018188 DOI: 10.3390/Ijms19072072  0.353
2018 Tentori AM, Nagarajan MB, Kim JJ, Zhang WC, Slack FJ, Doyle PS. Quantitative and multiplex microRNA assays from unprocessed cells in isolated nanoliter well arrays. Lab On a Chip. PMID 29998262 DOI: 10.1039/C8Lc00498F  0.477
2018 Anastasiadou E, Stroopinsky D, Alimperti S, Jiao AL, Pyzer AR, Cippitelli C, Pepe G, Severa M, Rosenblatt J, Etna MP, Rieger S, Kempkes B, Coccia EM, Sui SJH, Chen CS, ... ... Slack FJ, et al. Epstein-Barr virus-encoded EBNA2 alters immune checkpoint PD-L1 expression by downregulating miR-34a in B-cell lymphomas. Leukemia. PMID 29946193 DOI: 10.1038/S41375-018-0178-X  0.35
2018 Gilles ME, Hao L, Huang L, Rupaimoole R, Lopez-Casas PP, Pulver E, Jeong JC, Muthuswamy SK, Hidalgo M, Bhatia SN, Slack FJ. Personalized RNA-medicine for pancreatic cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 29330203 DOI: 10.1158/1078-0432.Ccr-17-2733  0.524
2018 Jiao AL, Foster DJ, Dixon J, Slack FJ. lin-4 and the NRDE pathway are required to activate a transgenic lin-4 reporter but not the endogenous lin-4 locus in C. elegans. Plos One. 13: e0190766. PMID 29324872 DOI: 10.1371/Journal.Pone.0190766  0.477
2018 Eleni A, Dina S, Alimperti S, Jiao A, Pyzer A, Cipitelli C, Severa M, Chen CS, Uccini S, Avigan D, Faggioni A, Trivedi P, Slack FJ. Abstract A16: Epstein-Barr virus encoded EBNA2 alters immune checkpoint PD-L1 expression by downregulating miR-34a in B cell lymphomas Cancer Immunology Research. 6. DOI: 10.1158/2326-6074.Tumimm17-A16  0.327
2018 Lee Jw, Slack FJ, Nestler EJ, Herbst RS, Koo JP. Abstract 3334: CREB is required for KRAS-driven lung tumorigenesis Cancer Research. 78: 3334-3334. DOI: 10.1158/1538-7445.Am2018-3334  0.35
2017 Anastasiadou E, Jacob LS, Slack FJ. Non-coding RNA networks in cancer. Nature Reviews. Cancer. PMID 29170536 DOI: 10.1038/Nrc.2017.99  0.379
2017 Inukai S, Pincus Z, de Lencastre A, Slack FJ. A microRNA feedback loop regulates global microRNA abundance during aging. Rna (New York, N.Y.). PMID 29114017 DOI: 10.1261/Rna.062190.117  0.546
2017 Metheetrairut C, Ahuja Y, Slack FJ. acn-1, a C. elegans homologue of ACE, genetically interacts with the let-7 microRNA and other heterochronic genes. Cell Cycle (Georgetown, Tex.). 1-10. PMID 28933985 DOI: 10.1080/15384101.2017.1344798  0.406
2017 Pyzer AR, Stroopinsky D, Rosenblatt J, Anastasiadou E, Rajabi H, Washington A, Tagde A, Chu JH, Coll M, Jiao AL, Tsai LT, Tenen DE, Cole L, Palmer K, Ephraim A, ... ... Slack F, et al. MUC1 inhibition leads to decrease in PD-L1 levels via up-regulation of miRNAs. Leukemia. PMID 28555079 DOI: 10.1038/Leu.2017.163  0.41
2017 Adams BD, Parsons C, Walker L, Zhang WC, Slack FJ. Targeting noncoding RNAs in disease. The Journal of Clinical Investigation. 127: 761-771. PMID 28248199 DOI: 10.1172/Jci84424  0.402
2017 Rupaimoole R, Slack FJ. MicroRNA therapeutics: towards a new era for the management of cancer and other diseases. Nature Reviews. Drug Discovery. PMID 28209991 DOI: 10.1038/Nrd.2016.246  0.557
2017 Stroopinsky D, Pyzer AR, Anastasiadou E, Rajabi H, Washington A, Tagde A, Coll M, Cole L, Palmer K, Somaiya P, Leaf RK, Nahas M, Apel A, Jain S, Joyce R, ... ... Slack F, et al. Abstract 54: MUC1-C regulates PD-L1 expression in acute myeloid leukemia, via downregulation of miRNAs Clinical Cancer Research. 23: 54-54. DOI: 10.1158/1557-3265.Hemmal17-54  0.484
2017 Zhang W, Slack F. MicroRNA-21 Mediates Resistance to EGFR Tyrosine Kinase Inhibitors in Lung Cancer Journal of Thoracic Oncology. 12: S1536. DOI: 10.1016/J.Jtho.2017.06.021  0.308
2016 Smith-Vikos T, Liu Z, Parsons C, Gorospe M, Ferrucci L, Gill TM, Slack FJ. A serum miRNA profile of human longevity: findings from the Baltimore Longitudinal Study of Aging (BLSA). Aging. PMID 27824314 DOI: 10.18632/aging.101106  0.839
2016 Rupaimoole R, Slack FJ. A role for miR-34 in colon cancer stem cell homeostasis. Stem Cell Investigation. 3: 42. PMID 27668249 DOI: 10.21037/Sci.2016.08.04  0.334
2016 Aigner A, Buesen R, Gant T, Gooderham N, Greim H, Hackermüller J, Hubesch B, Laffont M, Marczylo E, Meister G, Petrick JS, Rasoulpour RJ, Sauer UG, Schmidt K, Seitz H, ... Slack F, et al. Advancing the use of noncoding RNA in regulatory toxicology: Report of an ECETOC workshop. Regulatory Toxicology and Pharmacology : Rtp. PMID 27663666 DOI: 10.1016/J.Yrtph.2016.09.018  0.333
2016 Zhang WC, Slack FJ. ADARs Edit MicroRNAs to Promote Leukemic Stem Cell Activity. Cell Stem Cell. 19: 141-2. PMID 27494666 DOI: 10.1016/J.Stem.2016.07.012  0.302
2016 Svoronos AA, Engelman DM, Slack FJ. OncomiR or Tumor Suppressor? The Duplicity of MicroRNAs in Cancer. Cancer Research. PMID 27325641 DOI: 10.1158/0008-5472.Can-16-0359  0.556
2016 Metheetrairut C, Adams BD, Nallur S, Weidhaas JB, Slack FJ. cel-mir-237 and its homologue, hsa-miR-125b, modulate the cellular response to ionizing radiation. Oncogene. PMID 27321180 DOI: 10.1038/Onc.2016.222  0.692
2016 Salzman DW, Nakamura K, Nallur S, Dookwah MT, Metheetrairut C, Slack FJ, Weidhaas JB. miR-34 activity is modulated through 5'-end phosphorylation in response to DNA damage. Nature Communications. 7: 10954. PMID 26996824 DOI: 10.1038/Ncomms10954  0.848
2016 Kim M, Kogan N, Slack FJ. Cis-acting elements in its 3' UTR mediate post-transcriptional regulation of KRAS. Oncotarget. PMID 26930719 DOI: 10.18632/Oncotarget.7599  0.498
2016 Pyzer AR, Stroopinsky D, Rosenblatt J, Anastasiadou E, Rajabi H, Washington AJ, Tagde A, Coll MD, Cole L, Palmer KA, Somaiya P, Karp Leaf R, Nahas MR, Apel A, Jain S, ... ... Slack F, et al. MUC1-C Inhibition Leads to Decrease in PD-L1 Levels Via up-Regulation of Micro RNAs Blood. 128: 2871-2871. DOI: 10.1182/Blood.V128.22.2871.2871  0.501
2016 Fernández PP, Coira IF, Palomares EER, Romero OA, Metheetrairut C, Corral LB, Carretero J, Vidal EF, Celorrio MC, Zurita FR, Martín VS, Gavira CB, Cara JAL, Céspedes MS, Slack F, et al. Abstract 4479: Unveiling the relationship between the SWI/SNF chromatin remodeling complex and noncoding RNAs Cancer Research. 76: 4479-4479. DOI: 10.1158/1538-7445.Am2016-4479  0.466
2015 Adams BD, Wali VB, Cheng CJ, Inukai S, Booth CJ, Agarwal S, Rimm DL, Győrffy B, Santarpia L, Pusztai L, Saltzman WM, Slack FJ. miR-34a Silences c-SRC to Attenuate Tumor Growth in Triple Negative Breast Cancer. Cancer Research. PMID 26676753 DOI: 10.1158/0008-5472.Can-15-2321  0.437
2015 Adams BD, Parsons C, Slack FJ. The tumor-suppressive and potential therapeutic functions of miR-34a in epithelial carcinomas. Expert Opinion On Therapeutic Targets. 1-17. PMID 26652031 DOI: 10.1517/14728222.2016.1114102  0.52
2015 Adams BD, Anastasiadou E, Esteller M, He L, Slack FJ. The Inescapable Influence of Noncoding RNAs in Cancer. Cancer Research. PMID 26567137 DOI: 10.1158/0008-5472.Can-15-1989  0.491
2015 de Lencastre A, Slack F. Discovery of Novel microRNAs in Aging Caenorhabditis elegans. Methods in Molecular Biology (Clifton, N.J.). 1343: 235-48. PMID 26420721 DOI: 10.1007/978-1-4939-2963-4_18  0.307
2015 Woodbury ME, Freilich RW, Cheng CJ, Asai H, Ikezu S, Boucher JD, Slack F, Ikezu T. miR-155 Is Essential for Inflammation-Induced Hippocampal Neurogenic Dysfunction. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 35: 9764-81. PMID 26134658 DOI: 10.1523/Jneurosci.4790-14.2015  0.374
2015 McVeigh TP, Jung SY, Kerin MJ, Salzman DW, Nallur S, Nemec AA, Dookwah M, Sadofsky J, Paranjape T, Kelly O, Chan E, Miller N, Sweeney KJ, Zelterman D, Sweasy J, ... ... Slack FJ, et al. Estrogen withdrawal, increased breast cancer risk and the KRAS-variant. Cell Cycle (Georgetown, Tex.). 14: 2091-9. PMID 25961464 DOI: 10.1080/15384101.2015.1041694  0.781
2015 Stefani G, Chen X, Zhao H, Slack FJ. A novel mechanism of LIN-28 regulation of let-7 microRNA expression revealed by in vivo HITS-CLIP in C. elegans. Rna (New York, N.Y.). 21: 985-96. PMID 25805859 DOI: 10.1261/Rna.045542.114  0.419
2015 Stahlhut C, Slack FJ. Combinatorial Action of MicroRNAs let-7 and miR-34 Effectively Synergizes with Erlotinib to Suppress Non-small Cell Lung Cancer Cell Proliferation. Cell Cycle (Georgetown, Tex.). 14: 2171-80. PMID 25714397 DOI: 10.1080/15384101.2014.1003008  0.559
2015 Ling H, Vincent K, Pichler M, Fodde R, Berindan-Neagoe I, Slack FJ, Calin GA. Junk DNA and the long non-coding RNA twist in cancer genetics. Oncogene. PMID 25619839 DOI: 10.1038/Onc.2014.456  0.4
2015 Cheng CJ, Bahal R, Babar IA, Pincus Z, Barrera F, Liu C, Svoronos A, Braddock DT, Glazer PM, Engelman DM, Saltzman WM, Slack FJ. MicroRNA silencing for cancer therapy targeted to the tumour microenvironment. Nature. 518: 107-10. PMID 25409146 DOI: 10.1038/Nature13905  0.842
2015 Coira IF, Rufino-Palomares EE, Romero OA, Peinado P, Metheetrairut C, Boyero-Corral L, Carretero J, Farez-Vidal E, Cuadros M, Reyes-Zurita FJ, Lupiáñez JA, Sánchez-Cespedes M, Slack FJ, Medina PP. Expression inactivation of SMARCA4 by microRNAs in lung tumors. Human Molecular Genetics. 24: 1400-9. PMID 25355421 DOI: 10.1093/Hmg/Ddu554  0.514
2015 Kasinski AL, Kelnar K, Stahlhut C, Orellana E, Zhao J, Shimer E, Dysart S, Chen X, Bader AG, Slack FJ. A combinatorial microRNA therapeutics approach to suppressing non-small cell lung cancer. Oncogene. 34: 3547-55. PMID 25174400 DOI: 10.1038/Onc.2014.282  0.549
2015 Chen X, Paranjape T, Stahlhut C, McVeigh T, Keane F, Nallur S, Miller N, Kerin M, Deng Y, Yao X, Zhao H, Weidhaas JB, Slack FJ. Targeted resequencing of the microRNAome and 3'UTRome reveals functional germline DNA variants with altered prevalence in epithelial ovarian cancer. Oncogene. 34: 2125-37. PMID 24909162 DOI: 10.1038/Onc.2014.117  0.632
2015 Adams BD, Pusztai L, Rimm DL, Slack FJ. Abstract P4-07-12: Re-introduction of tumor suppressor miR-34a harbors therapeutic efficacy in triple negative breast cancer Cancer Research. 75. DOI: 10.1158/1538-7445.Sabcs14-P4-07-12  0.412
2015 Adams BD, Wali V, Cheng C, Inukai S, Rimm D, Pusztai L, Saltzman M, Slack F. Abstract LB-300: Reintroduction of tumor-suppressor miR-34a shows therapeutic efficacy in triple-negative breast cancer Cancer Research. 75. DOI: 10.1158/1538-7445.Am2015-Lb-300  0.409
2015 Engelman DM, Cheng CJ, Bahal R, Babar IA, Pincus Z, Barrera FN, Liu C, Svoronos A, Braddock DT, Glazer PM, Saltzman WM, Slack FJ. pHLIP® Targeting and Delivery of PNA to Silence MicroRNA in Tumor Cells§ Biophysical Journal. 108: 552a. DOI: 10.1016/J.Bpj.2014.11.3029  0.822
2014 Anastasiadou E, Slack FJ. Cancer. Malicious exosomes. Science (New York, N.Y.). 346: 1459-60. PMID 25525233 DOI: 10.1126/Science.Aaa4024  0.331
2014 Kim M, Slack FJ. MicroRNA-mediated regulation of KRAS in cancer. Journal of Hematology & Oncology. 7: 84. PMID 25433809 DOI: 10.1186/S13045-014-0084-2  0.567
2014 Smith-Vikos T, de Lencastre A, Inukai S, Shlomchik M, Holtrup B, Slack FJ. MicroRNAs mediate dietary-restriction-induced longevity through PHA-4/FOXA and SKN-1/Nrf transcription factors. Current Biology : Cb. 24: 2238-46. PMID 25242029 DOI: 10.1016/J.Cub.2014.08.013  0.821
2014 Adams BD, Kasinski AL, Slack FJ. Aberrant regulation and function of microRNAs in cancer. Current Biology : Cb. 24: R762-76. PMID 25137592 DOI: 10.1016/J.Cub.2014.06.043  0.561
2014 Chu YD, Wang WC, Chen SA, Hsu YT, Yeh MW, Slack FJ, Chan SP. RACK-1 regulates let-7 microRNA expression and terminal cell differentiation in Caenorhabditis elegans. Cell Cycle (Georgetown, Tex.). 13: 1995-2009. PMID 24776851 DOI: 10.4161/Cc.29017  0.57
2014 Slack FJ. In this issue of Epigenetics: special focus on non-coding RNAs in epigenetic regulation. Epigenetics. 9: 1-2. PMID 24739672 DOI: 10.4161/Epi.27579  0.389
2014 Kim M, Chen X, Chin LJ, Paranjape T, Speed WC, Kidd KK, Zhao H, Weidhaas JB, Slack FJ. Extensive sequence variation in the 3' untranslated region of the KRAS gene in lung and ovarian cancer cases. Cell Cycle (Georgetown, Tex.). 13: 1030-40. PMID 24552817 DOI: 10.4161/Cc.27941  0.852
2014 Turner MJ, Jiao AL, Slack FJ. Autoregulation of lin-4 microRNA transcription by RNA activation (RNAa) in C. elegans. Cell Cycle (Georgetown, Tex.). 13: 772-81. PMID 24398561 DOI: 10.4161/Cc.27679  0.475
2014 Jiao AL, Slack FJ. RNA-mediated gene activation. Epigenetics. 9: 27-36. PMID 24185374 DOI: 10.4161/Epi.26942  0.315
2014 Weidhaas JB, Kim ES, Herbst RS, Yu J, Slack F, Blumenschein GR, Tsao AS, Wistuba II, Lee JJ, Papadimitrakopoulou V, Hong WK, Heymach J, Tran HT. The KRAS-variant and treatment response in BATTLE-1. Journal of Clinical Oncology. 32: 8135-8135. DOI: 10.1200/Jco.2014.32.15_Suppl.8135  0.589
2014 Cheng CJ, Engelman DM, Saltzman M, Slack FJ. Abstract 974: Targeting the tumor microenvironment with antimiRs that exploit oncomiR addiction in lymphoma Cancer Research. 74: 974-974. DOI: 10.1158/1538-7445.Am2014-974  0.453
2013 Stahlhut C, Slack FJ. MicroRNAs and the cancer phenotype: profiling, signatures and clinical implications. Genome Medicine. 5: 111. PMID 24373327 DOI: 10.1186/Gm516  0.554
2013 Kasinski A, Slack FJ. Small RNAs deliver a blow to ovarian cancer. Cancer Discovery. 3: 1220-1. PMID 24203953 DOI: 10.1158/2159-8290.Cd-13-0667  0.326
2013 Higgs G, Slack F. The multiple roles of microRNA-155 in oncogenesis. Journal of Clinical Bioinformatics. 3: 17. PMID 24073882 DOI: 10.1186/2043-9113-3-17  0.494
2013 Smith-Vikos T, Slack FJ. MicroRNAs circulate around Alzheimer's disease. Genome Biology. 14: 125. PMID 23889814 DOI: 10.1186/Gb-2013-14-7-125  0.772
2013 Lieberman J, Slack F, Pandolfi PP, Chinnaiyan A, Agami R, Mendell JT. Noncoding RNAs and cancer. Cell. 153: 9-10. PMID 23781554 DOI: 10.1016/J.Cell.2013.03.019  0.33
2013 Chen X, Slack FJ, Zhao H. Joint analysis of expression profiles from multiple cancers improves the identification of microRNA-gene interactions. Bioinformatics (Oxford, England). 29: 2137-45. PMID 23772050 DOI: 10.1093/Bioinformatics/Btt341  0.537
2013 Cheng CJ, Saltzman WM, Slack FJ. Canonical and non-canonical barriers facing antimiR cancer therapeutics. Current Medicinal Chemistry. 20: 3582-93. PMID 23745563 DOI: 10.2174/0929867311320290004  0.538
2013 Metheetrairut C, Slack FJ. MicroRNAs in the ionizing radiation response and in radiotherapy. Current Opinion in Genetics & Development. 23: 12-9. PMID 23453900 DOI: 10.1016/J.Gde.2013.01.002  0.508
2013 Inukai S, Slack F. MicroRNAs and the genetic network in aging. Journal of Molecular Biology. 425: 3601-8. PMID 23353823 DOI: 10.1016/J.Jmb.2013.01.023  0.534
2013 Hoffman AE, Liu R, Fu A, Zheng T, Slack F, Zhu Y. Targetome profiling, pathway analysis and genetic association study implicate miR-202 in lymphomagenesis. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. 22: 327-36. PMID 23334589 DOI: 10.1158/1055-9965.Epi-12-1131-T  0.451
2013 Slack FJ. MicroRNAs regulate expression of oncogenes. Clinical Chemistry. 59: 325-6. PMID 22529108 DOI: 10.1373/Clinchem.2011.181016  0.581
2013 Kato M, Slack FJ. Ageing and the small, non-coding RNA world. Ageing Research Reviews. 12: 429-35. PMID 22504407 DOI: 10.1016/J.Arr.2012.03.012  0.331
2012 Kasinski AL, Slack FJ. Arresting the Culprit: Targeted Antagomir Delivery to Sequester Oncogenic miR-221 in HCC. Molecular Therapy. Nucleic Acids. 1: e12. PMID 23343881 DOI: 10.1038/Mtna.2012.2  0.446
2012 Chen PY, Qin L, Barnes C, Charisse K, Yi T, Zhang X, Ali R, Medina PP, Yu J, Slack FJ, Anderson DG, Kotelianski V, Wang F, Tellides G, Simons M. FGF regulates TGF-β signaling and endothelial-to-mesenchymal transition via control of let-7 miRNA expression. Cell Reports. 2: 1684-96. PMID 23200853 DOI: 10.1016/J.Celrep.2012.10.021  0.339
2012 Jiao A, Slack FJ. MicroRNAs micromanage themselves. Circulation Research. 111: 1395-7. PMID 23139285 DOI: 10.1161/Circresaha.112.281014  0.54
2012 Kasinski AL, Slack FJ. miRNA-34 prevents cancer initiation and progression in a therapeutically resistant K-ras and p53-induced mouse model of lung adenocarcinoma. Cancer Research. 72: 5576-87. PMID 22964582 DOI: 10.1158/0008-5472.Can-12-2001  0.481
2012 Inukai S, de Lencastre A, Turner M, Slack F. Novel microRNAs differentially expressed during aging in the mouse brain. Plos One. 7: e40028. PMID 22844398 DOI: 10.1371/Journal.Pone.0040028  0.53
2012 Babar IA, Cheng CJ, Booth CJ, Liang X, Weidhaas JB, Saltzman WM, Slack FJ. Nanoparticle-based therapy in an in vivo microRNA-155 (miR-155)-dependent mouse model of lymphoma. Proceedings of the National Academy of Sciences of the United States of America. 109: E1695-704. PMID 22685206 DOI: 10.1073/Pnas.1201516109  0.813
2012 Cheng CJ, Slack FJ. The duality of oncomiR addiction in the maintenance and treatment of cancer. Cancer Journal (Sudbury, Mass.). 18: 232-7. PMID 22647359 DOI: 10.1097/Ppo.0B013E318258B75B  0.562
2012 Hanna JA, Wimberly H, Kumar S, Slack F, Agarwal S, Rimm DL. Quantitative analysis of microRNAs in tissue microarrays by in situ hybridization. Biotechniques. 52: 235-45. PMID 22482439 DOI: 10.2144/000113837  0.572
2012 Inukai S, Slack FJ. MiR-33 connects cholesterol to the cell cycle. Cell Cycle (Georgetown, Tex.). 11: 1060-1. PMID 22391211 DOI: 10.4161/Cc.11.6.19786  0.356
2012 Stefani G, Slack FJ. A 'pivotal' new rule for microRNA-mRNA interactions. Nature Structural & Molecular Biology. 19: 265-6. PMID 22388780 DOI: 10.1038/Nsmb.2256  0.53
2012 Smith-Vikos T, Slack FJ. MicroRNAs and their roles in aging. Journal of Cell Science. 125: 7-17. PMID 22294612 DOI: 10.1242/Jcs.099200  0.842
2012 Russ R, Slack FJ. Cigarette-Smoke-Induced Dysregulation of MicroRNA Expression and Its Role in Lung Carcinogenesis. Pulmonary Medicine. 2012: 791234. PMID 22191027 DOI: 10.1155/2012/791234  0.492
2012 Kundu ST, Nallur S, Paranjape T, Boeke M, Weidhaas JB, Slack FJ. KRAS alleles: the LCS6 3'UTR variant and KRAS coding sequence mutations in the NCI-60 panel. Cell Cycle (Georgetown, Tex.). 11: 361-6. PMID 22189714 DOI: 10.4161/Cc.11.2.18794  0.672
2012 Ratner ES, Keane FK, Lindner R, Tassi RA, Paranjape T, Glasgow M, Nallur S, Deng Y, Lu L, Steele L, Sand S, Muller RU, Bignotti E, Bellone S, Boeke M, ... ... Slack FJ, et al. A KRAS variant is a biomarker of poor outcome, platinum chemotherapy resistance and a potential target for therapy in ovarian cancer. Oncogene. 31: 4559-66. PMID 22139083 DOI: 10.1038/Onc.2011.539  0.666
2012 Kasinski AL, Slack FJ. Abstract 2950: miR-34 preventsin vivolung tumor initiation and progression in the therapeutically resistant Kras;p53 mouse model Cancer Research. 72: 2950-2950. DOI: 10.1158/1538-7445.Am2012-2950  0.432
2012 Hoffman AE, Liu R, Zheng T, Fu A, Slack F, Zhu Y. Abstract 1652: Targetome profiling and genetic association analyses implicate miR-202 in follicular lymphomagenesis Cancer Research. 72: 1652-1652. DOI: 10.1158/1538-7445.Am2012-1652  0.503
2012 Slack FJ. Abstract IA1: microRNAs and lung cancer Clinical Cancer Research. 18: IA1-IA1. DOI: 10.1158/1078-0432.12Aacriaslc-Ia1  0.474
2011 Blum JS, Weller CE, Booth CJ, Babar IA, Liang X, Slack FJ, Saltzman WM. Prevention of K-Ras- and Pten-mediated intravaginal tumors by treatment with camptothecin-loaded PLGA nanoparticles. Drug Delivery and Translational Research. 1: 383-394. PMID 25419505 DOI: 10.1007/S13346-011-0038-Y  0.757
2011 Van Wynsberghe PM, Chan SP, Slack FJ, Pasquinelli AE. Analysis of microRNA Expression and Function Methods in Cell Biology. 106: 219-252. PMID 22118279 DOI: 10.1016/B978-0-12-544172-8.00008-6  0.546
2011 Kasinski AL, Slack FJ. Epigenetics and genetics. MicroRNAs en route to the clinic: progress in validating and targeting microRNAs for cancer therapy. Nature Reviews. Cancer. 11: 849-64. PMID 22113163 DOI: 10.1038/Nrc3166  0.57
2011 Landau DA, Slack FJ. MicroRNAs in mutagenesis, genomic instability, and DNA repair. Seminars in Oncology. 38: 743-51. PMID 22082760 DOI: 10.1053/J.Seminoncol.2011.08.003  0.52
2011 Babar IA, Czochor J, Steinmetz A, Weidhaas JB, Glazer PM, Slack FJ. Inhibition of hypoxia-induced miR-155 radiosensitizes hypoxic lung cancer cells. Cancer Biology & Therapy. 12: 908-14. PMID 22027557 DOI: 10.4161/Cbt.12.10.17681  0.822
2011 Weidhaas JB, Slack FJ. KRAS rs61764370 in Epithelial Ovarian Cancer-Letter. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 17: 6600; author reply 6. PMID 22003074 DOI: 10.1158/1078-0432.Ccr-11-1195  0.591
2011 Pincus Z, Smith-Vikos T, Slack FJ. MicroRNA predictors of longevity in Caenorhabditis elegans. Plos Genetics. 7: e1002306. PMID 21980307 DOI: 10.1371/Journal.Pgen.1002306  0.807
2011 Kato M, Chen X, Inukai S, Zhao H, Slack FJ. Age-associated changes in expression of small, noncoding RNAs, including microRNAs, in C. elegans. Rna (New York, N.Y.). 17: 1804-20. PMID 21810936 DOI: 10.1261/Rna.2714411  0.523
2011 Chan E, Patel R, Nallur S, Ratner E, Bacchiocchi A, Hoyt K, Szpakowski S, Godshalk S, Ariyan S, Sznol M, Halaban R, Krauthammer M, Tuck D, Slack FJ, Weidhaas JB. MicroRNA signatures differentiate melanoma subtypes. Cell Cycle (Georgetown, Tex.). 10: 1845-52. PMID 21543894 DOI: 10.4161/Cc.10.11.15777  0.845
2011 Kim M, Kasinski AL, Slack FJ. MicroRNA therapeutics in preclinical cancer models. The Lancet. Oncology. 12: 319-21. PMID 21463831 DOI: 10.1016/S1470-2045(11)70067-5  0.419
2011 Paranjape T, Heneghan H, Lindner R, Keane FK, Hoffman A, Hollestelle A, Dorairaj J, Geyda K, Pelletier C, Nallur S, Martens JW, Hooning MJ, Kerin M, Zelterman D, Zhu Y, ... ... Slack F, et al. A 3'-untranslated region KRAS variant and triple-negative breast cancer: a case-control and genetic analysis. The Lancet. Oncology. 12: 377-86. PMID 21435948 DOI: 10.1016/S1470-2045(11)70044-4  0.67
2011 Trang P, Wiggins JF, Daige CL, Cho C, Omotola M, Brown D, Weidhaas JB, Bader AG, Slack FJ. Systemic delivery of tumor suppressor microRNA mimics using a neutral lipid emulsion inhibits lung tumors in mice. Molecular Therapy : the Journal of the American Society of Gene Therapy. 19: 1116-22. PMID 21427705 DOI: 10.1038/Mt.2011.48  0.707
2011 Pelletier C, Speed WC, Paranjape T, Keane K, Blitzblau R, Hollestelle A, Safavi K, van den Ouweland A, Zelterman D, Slack FJ, Kidd KK, Weidhaas JB. Rare BRCA1 haplotypes including 3'UTR SNPs associated with breast cancer risk. Cell Cycle (Georgetown, Tex.). 10: 90-9. PMID 21191178 DOI: 10.4161/Cc.10.1.14359  0.619
2011 Lu ZJ, Yip KY, Wang G, Shou C, Hillier LW, Khurana E, Agarwal A, Auerbach R, Rozowsky J, Cheng C, Kato M, Miller DM, Slack F, Snyder M, Waterston RH, et al. Prediction and characterization of noncoding RNAs in C. elegans by integrating conservation, secondary structure, and high-throughput sequencing and array data. Genome Research. 21: 276-85. PMID 21177971 DOI: 10.1101/Gr.110189.110  0.321
2011 Godshalk SE, Paranjape T, Nallur S, Speed W, Chan E, Molinaro AM, Bacchiocchi A, Hoyt K, Tworkoski K, Stern DF, Sznol M, Ariyan S, Lazova R, Halaban R, Kidd KK, ... ... Slack FJ, et al. A Variant in a MicroRNA complementary site in the 3' UTR of the KIT oncogene increases risk of acral melanoma. Oncogene. 30: 1542-50. PMID 21119596 DOI: 10.1038/Onc.2010.536  0.847
2011 Weidhaas J, Slack F, Miller N, Harris L, Tuck D, Zhu Y, Zelterman D, Kerin M, Paranjape T, Heneghan H, Lindner R, Keane F, Dorairaj J, Geyda K, Pelletier C, et al. Association between KRAS rs61764370 and triple-negative breast cancer-a false positive? - Authors' reply The Lancet Oncology. 12: 724. DOI: 10.1016/S1470-2045(11)70163-2  0.565
2011 Ratner E, Keane F, Yu H, Zelterman D, Rutherford T, Santin A, Schwartz P, Slack F, Levine D, Weidhaas J. A 3′ UTR KRAS variant as a biomarker of poor outcome and chemotherapy resistance in ovarian cancer (Gynecologic Oncology (2011) 120, (S3)) Gynecologic Oncology. 122: 205. DOI: 10.1016/J.Ygyno.2011.03.028  0.586
2011 Ratner E, Keane F, Yu H, Zelterman D, Rutherford T, Santin A, Schwartz P, Slack F, Levine D, Weidhaas J. RETRACTED: A 3’ UTR KRAS variant as a biomarker of poor outcome and chemotherapy resistance in ovarian cancer Gynecologic Oncology. 120: S3. DOI: 10.1016/J.Ygyno.2010.12.010  0.573
2010 de Lencastre A, Pincus Z, Zhou K, Kato M, Lee SS, Slack FJ. MicroRNAs both promote and antagonize longevity in C. elegans. Current Biology : Cb. 20: 2159-68. PMID 21129974 DOI: 10.1016/J.Cub.2010.11.015  0.515
2010 Medina PP, Nolde M, Slack FJ. OncomiR addiction in an in vivo model of microRNA-21-induced pre-B-cell lymphoma. Nature. 467: 86-90. PMID 20693987 DOI: 10.1038/Nature09284  0.85
2010 Hada K, Asahina M, Hasegawa H, Kanaho Y, Slack FJ, Niwa R. The nuclear receptor gene nhr-25 plays multiple roles in the Caenorhabditis elegans heterochronic gene network to control the larva-to-adult transition. Developmental Biology. 344: 1100-9. PMID 20678979 DOI: 10.1016/J.Ydbio.2010.05.508  0.344
2010 Ratner E, Lu L, Boeke M, Barnett R, Nallur S, Chin LJ, Pelletier C, Blitzblau R, Tassi R, Paranjape T, Hui P, Godwin AK, Yu H, Risch H, Rutherford T, ... ... Slack FJ, et al. A KRAS-variant in ovarian cancer acts as a genetic marker of cancer risk. Cancer Research. 70: 6509-15. PMID 20647319 DOI: 10.1158/0008-5472.Can-10-0689  0.811
2010 Kasinski AL, Slack FJ. Potential microRNA therapies targeting Ras, NFkappaB and p53 signaling. Current Opinion in Molecular Therapeutics. 12: 147-57. PMID 20373258  0.455
2010 Kundu ST, Slack FJ. Robust and specific inhibition of microRNAs in Caenorhabditis elegans. Journal of Biology. 9: 20. PMID 20359318 DOI: 10.1186/Jbiol230  0.553
2010 Godshalk SE, Melnik-Martinez KV, Pasquinelli AE, Slack FJ. MicroRNAs and cancer: a meeting summary of the eponymous Keystone Conference. Epigenetics. 5: 164-8. PMID 20168081 DOI: 10.4161/Epi.5.2.11162  0.853
2010 Slack FJ. Stem cells: Big roles for small RNAs. Nature. 463: 616. PMID 20130638 DOI: 10.1038/463616A  0.34
2010 Trang P, Medina PP, Wiggins JF, Ruffino L, Kelnar K, Omotola M, Homer R, Brown D, Bader AG, Weidhaas JB, Slack FJ. Regression of murine lung tumors by the let-7 microRNA. Oncogene. 29: 1580-7. PMID 19966857 DOI: 10.1038/Onc.2009.445  0.69
2010 Paranjape TS, Heneghan H, Pelletier C, Hoffman A, Kerin MJ, Harris L, Zhu Y, Miller N, Zelterman D, Tuck D, Slack F, Weidhaas J. Abstract 3029: A KRAS microRNA binding site polymorphism as a novel biomarker of risk in triple negative breast cancer Cancer Research. 70: 3029-3029. DOI: 10.1158/1538-7445.Am10-3029  0.725
2010 Weidhaas JB, Slack F. Abstract 1856: A KRAS-variant as a putative biomarker of ovarian cancer risk Cancer Research. 70: 1856-1856. DOI: 10.1158/1538-7445.Am10-1856  0.621
2010 Heneghan H, Miller N, Paranjape T, Slack F, Weidhaas J, Kerin M. O-43 A KRAS microRNA binding site variant is a genetic marker of risk for triple negative breast cancer European Journal of Cancer Supplements. 8: 16. DOI: 10.1016/J.Ejcsup.2010.06.044  0.6
2009 Niwa R, Hada K, Moliyama K, Ohniwa RL, Tan YM, Olsson-Carter K, Chi W, Reinke V, Slack FJ. C. elegans sym-1 is a downstream target of the hunchback-like-1 developmental timing transcription factor. Cell Cycle (Georgetown, Tex.). 8: 4147-54. PMID 19923914 DOI: 10.4161/Cc.8.24.10292  0.419
2009 Paranjape T, Slack FJ, Weidhaas JB. MicroRNAs: Tools for cancer diagnostics Gut. 58: 1546-1554. PMID 19834118 DOI: 10.1136/Gut.2009.179531  0.741
2009 Roush SF, Slack FJ. Transcription of the C. elegans let-7 microRNA is temporally regulated by one of its targets, hbl-1. Developmental Biology. 334: 523-34. PMID 19627983 DOI: 10.1016/J.Ydbio.2009.07.012  0.815
2009 Chan SP, Slack FJ. Ribosomal protein RPS-14 modulates let-7 microRNA function in Caenorhabditis elegans. Developmental Biology. 334: 152-60. PMID 19627982 DOI: 10.1016/J.Ydbio.2009.07.011  0.542
2009 Hoffman AE, Zheng T, Yi C, Leaderer D, Weidhaas J, Slack F, Zhang Y, Paranjape T, Zhu Y. microRNA miR-196a-2 and breast cancer: a genetic and epigenetic association study and functional analysis. Cancer Research. 69: 5970-7. PMID 19567675 DOI: 10.1158/0008-5472.Can-09-0236  0.722
2009 Kato M, de Lencastre A, Pincus Z, Slack FJ. Dynamic expression of small non-coding RNAs, including novel microRNAs and piRNAs/21U-RNAs, during Caenorhabditis elegans development. Genome Biology. 10: R54. PMID 19460142 DOI: 10.1186/Gb-2009-10-5-R54  0.421
2009 Kato M, Paranjape T, Müller RU, Ullrich R, Nallur S, Gillespie E, Keane K, Esquela-Kerscher A, Weidhaas JB, Slack FJ. The mir-34 microRNA is required for the DNA damage response in vivo in C. elegans and in vitro in human breast cancer cells. Oncogene. 28: 2419-24. PMID 19421141 DOI: 10.1038/Onc.2009.106  0.844
2009 Slack F. let-7 microRNA reduces tumor growth. Cell Cycle (Georgetown, Tex.). 8: 1823. PMID 19377282 DOI: 10.4161/Cc.8.12.8639  0.363
2009 Nimmo RA, Slack FJ. An elegant miRror: microRNAs in stem cells, developmental timing and cancer. Chromosoma. 118: 405-18. PMID 19340450 DOI: 10.1007/S00412-009-0210-Z  0.49
2009 Corbin R, Olsson-Carter K, Slack F. The role of microRNAs in synaptic development and function. Bmb Reports. 42: 131-5. PMID 19335998 DOI: 10.5483/Bmbrep.2009.42.3.131  0.474
2009 Medina PP, Slack FJ. Inhibiting microRNA function in vivo. Nature Methods. 6: 37-8. PMID 19116612 DOI: 10.1038/Nmeth0109-37  0.538
2009 Turner MJ, Slack FJ. Transcriptional control of microRNA expression in C. elegans: promoting better understanding. Rna Biology. 6: 49-53. PMID 19106630 DOI: 10.4161/Rna.6.1.7574  0.555
2009 Duchaine TF, Slack FJ. RNA interference and micro-RNA-oriented therapy in cancer: Rationales, promises, and challenges Current Oncology. 16: 61-66. DOI: 10.3747/Co.V16I4.486  0.451
2009 Paranjape T, Nallur S, Keanie K, Martel M, Haffty B, Tuck D, Slack F, Weidhaas J. MicroRNA profiling of triple negative breast cancer: predicting outcome and targets. Cancer Research. 69: 2040. DOI: 10.1158/0008-5472.Sabcs-2040  0.614
2008 Trang P, Weidhaas JB, Slack FJ. MicroRNAs as potential cancer therapeutics Oncogene. 27. PMID 19956180 DOI: 10.1038/Onc.2009.353  0.735
2008 Maller Schulman BR, Liang X, Stahlhut C, DelConte C, Stefani G, Slack FJ. The let-7 microRNA target gene, Mlin41/Trim71 is required for mouse embryonic survival and neural tube closure. Cell Cycle (Georgetown, Tex.). 7: 3935-42. PMID 19098426 DOI: 10.4161/Cc.7.24.7397  0.503
2008 Slack FJ, Weidhaas JB. MicroRNA in cancer prognosis. The New England Journal of Medicine. 359: 2720-2. PMID 19092157 DOI: 10.1056/Nejme0808667  0.669
2008 Godshalk SE, Bhaduri-McIntosh S, Slack FJ. Epstein-Barr virus-mediated dysregulation of human microRNA expression. Cell Cycle (Georgetown, Tex.). 7: 3595-600. PMID 19001862 DOI: 10.4161/Cc.7.22.7120  0.849
2008 Chin LJ, Ratner E, Leng S, Zhai R, Nallur S, Babar I, Muller RU, Straka E, Su L, Burki EA, Crowell RE, Patel R, Kulkarni T, Homer R, Zelterman D, ... ... Slack FJ, et al. A SNP in a let-7 microRNA complementary site in the KRAS 3' untranslated region increases non-small cell lung cancer risk. Cancer Research. 68: 8535-40. PMID 18922928 DOI: 10.1158/0008-5472.Can-08-2129  0.804
2008 Chin LJ, Slack FJ. A truth serum for cancer--microRNAs have major potential as cancer biomarkers. Cell Research. 18: 983-4. PMID 18833286 DOI: 10.1038/Cr.2008.290  0.76
2008 Pincus Z, Slack FJ. Transcriptional (dys)regulation and aging in Caenorhabditis elegans. Genome Biology. 9: 233. PMID 18828877 DOI: 10.1186/Gb-2008-9-9-233  0.308
2008 Ding XC, Slack FJ, Grosshans H. The let-7 microRNA interfaces extensively with the translation machinery to regulate cell differentiation. Cell Cycle (Georgetown, Tex.). 7: 3083-90. PMID 18818519 DOI: 10.4161/Cc.7.19.6778  0.532
2008 Roush S, Slack FJ. The let-7 family of microRNAs. Trends in Cell Biology. 18: 505-16. PMID 18774294 DOI: 10.1016/J.Tcb.2008.07.007  0.841
2008 Medina PP, Slack FJ. microRNAs and cancer: an overview. Cell Cycle (Georgetown, Tex.). 7: 2485-92. PMID 18719380 DOI: 10.4161/Cc.7.16.6453  0.586
2008 Chan SP, Ramaswamy G, Choi EY, Slack FJ. Identification of specific let-7 microRNA binding complexes in Caenorhabditis elegans. Rna (New York, N.Y.). 14: 2104-14. PMID 18719242 DOI: 10.1261/Rna.551208  0.43
2008 Büssing I, Slack FJ, Grosshans H. let-7 microRNAs in development, stem cells and cancer. Trends in Molecular Medicine. 14: 400-9. PMID 18674967 DOI: 10.1016/J.Molmed.2008.07.001  0.548
2008 Babar IA, Slack FJ, Weidhaas JB. miRNA modulation of the cellular stress response. Future Oncology (London, England). 4: 289-98. PMID 18407740 DOI: 10.2217/14796694.4.2.289  0.83
2008 Esquela-Kerscher A, Trang P, Wiggins JF, Patrawala L, Cheng A, Ford L, Weidhaas JB, Brown D, Bader AG, Slack FJ. The let-7 microRNA reduces tumor growth in mouse models of lung cancer. Cell Cycle (Georgetown, Tex.). 7: 759-64. PMID 18344688 DOI: 10.4161/Cc.7.6.5834  0.809
2008 Stefani G, Slack FJ. Small non-coding RNAs in animal development. Nature Reviews. Molecular Cell Biology. 9: 219-30. PMID 18270516 DOI: 10.1038/Nrm2347  0.482
2008 Niwa R, Zhou F, Li C, Slack FJ. The expression of the Alzheimer's amyloid precursor protein-like gene is regulated by developmental timing microRNAs and their targets in Caenorhabditis elegans. Developmental Biology. 315: 418-25. PMID 18262516 DOI: 10.1016/J.Ydbio.2007.12.044  0.35
2008 Kato M, Slack FJ. microRNAs: small molecules with big roles - C. elegans to human cancer. Biology of the Cell / Under the Auspices of the European Cell Biology Organization. 100: 71-81. PMID 18199046 DOI: 10.1042/Bc20070078  0.561
2007 Weidhaas JB, Babar I, Nallur SM, Trang P, Roush S, Boehm M, Gillespie E, Slack FJ. MicroRNAs as potential agents to alter resistance to cytotoxic anticancer therapy. Cancer Research. 67: 11111-6. PMID 18056433 DOI: 10.1158/0008-5472.Can-07-2858  0.824
2007 Chan SP, Slack FJ. And now introducing mammalian mirtrons. Developmental Cell. 13: 605-7. PMID 17981129 DOI: 10.1016/J.Devcel.2007.10.010  0.313
2007 Johnson CD, Esquela-Kerscher A, Stefani G, Byrom M, Kelnar K, Ovcharenko D, Wilson M, Wang X, Shelton J, Shingara J, Chin L, Brown D, Slack FJ. The let-7 microRNA represses cell proliferation pathways in human cells. Cancer Research. 67: 7713-22. PMID 17699775 DOI: 10.1158/0008-5472.Can-07-1083  0.806
2007 Nolde MJ, Saka N, Reinert KL, Slack FJ. The Caenorhabditis elegans pumilio homolog, puf-9, is required for the 3'UTR-mediated repression of the let-7 microRNA target gene, hbl-1. Developmental Biology. 305: 551-63. PMID 17412319 DOI: 10.1016/J.Ydbio.2007.02.040  0.829
2007 Niwa R, Slack FJ. The evolution of animal microRNA function. Current Opinion in Genetics & Development. 17: 145-50. PMID 17317150 DOI: 10.1016/J.Gde.2007.02.004  0.543
2007 Weidhaas J, Slack F, Babar I, Nallur S. Using MicroRNAs to Alter the Radiation Response International Journal of Radiation Oncology*Biology*Physics. 69: S145-S146. DOI: 10.1016/J.Ijrobp.2007.07.266  0.78
2006 Stahlhut Espinosa CE, Slack FJ. The role of microRNAs in cancer. The Yale Journal of Biology and Medicine. 79: 131-40. PMID 17940623  0.396
2006 Stefani G, Slack F. MicroRNAs in search of a target Cold Spring Harbor Symposia On Quantitative Biology. 71: 129-134. PMID 17381288 DOI: 10.1101/Sqb.2006.71.032  0.494
2006 Chan SP, Slack FJ. microRNA-mediated silencing inside P-bodies. Rna Biology. 3: 97-100. PMID 17179742 DOI: 10.4161/Rna.3.3.3499  0.326
2006 Roush SF, Slack FJ. Micromanagement: a role for microRNAs in mRNA stability. Acs Chemical Biology. 1: 132-4. PMID 17163657 DOI: 10.1021/Cb600138J  0.798
2006 Boehm M, Slack FJ. MicroRNA control of lifespan and metabolism. Cell Cycle (Georgetown, Tex.). 5: 837-40. PMID 16627994 DOI: 10.4161/Cc.5.8.2688  0.809
2006 Esquela-Kerscher A, Slack FJ. Oncomirs - microRNAs with a role in cancer. Nature Reviews. Cancer. 6: 259-69. PMID 16557279 DOI: 10.1038/Nrc1840  0.841
2006 Slack FJ, Weidhaas JB. MicroRNAs as a potential magic bullet in cancer. Future Oncology (London, England). 2: 73-82. PMID 16556074 DOI: 10.2217/14796694.2.1.73  0.724
2006 Boehm M, Slack F. A developmental timing microRNA and its target regulate life span in C. elegans. Science (New York, N.Y.). 310: 1954-7. PMID 16373574 DOI: 10.1126/Science.1115596  0.795
2005 Vella MC, Slack FJ. C. elegans microRNAs. Wormbook : the Online Review of C. Elegans Biology. 1-9. PMID 18050425 DOI: 10.1895/Wormbook.1.26.1  0.796
2005 Schulman BR, Esquela-Kerscher A, Slack FJ. Reciprocal expression of lin-41 and the microRNAs let-7 and mir-125 during mouse embryogenesis. Developmental Dynamics : An Official Publication of the American Association of Anatomists. 234: 1046-54. PMID 16247770 DOI: 10.1002/Dvdy.20599  0.838
2005 Esquela-Kerscher A, Johnson SM, Bai L, Saito K, Partridge J, Reinert KL, Slack FJ. Post-embryonic expression of C. elegans microRNAs belonging to the lin-4 and let-7 families in the hypodermis and the reproductive system. Developmental Dynamics : An Official Publication of the American Association of Anatomists. 234: 868-77. PMID 16217741 DOI: 10.1002/Dvdy.20572  0.821
2005 Johnson SM, Grosshans H, Shingara J, Byrom M, Jarvis R, Cheng A, Labourier E, Reinert KL, Brown D, Slack FJ. RAS is regulated by the let-7 microRNA family. Cell. 120: 635-47. PMID 15766527 DOI: 10.1016/J.Cell.2005.01.014  0.455
2005 Grosshans H, Johnson T, Reinert KL, Gerstein M, Slack FJ. The temporal patterning microRNA let-7 regulates several transcription factors at the larval to adult transition in C. elegans. Developmental Cell. 8: 321-30. PMID 15737928 DOI: 10.1016/J.Devcel.2004.12.019  0.417
2005 Banerjee D, Kwok A, Lin SY, Slack FJ. Developmental timing in C. elegans is regulated by kin-20 and tim-1, homologs of core circadian clock genes. Developmental Cell. 8: 287-95. PMID 15691769 DOI: 10.1016/J.Devcel.2004.12.006  0.306
2004 Esquela-Kerscher A, Slack FJ. The age of high-throughput microRNA profiling. Nature Methods. 1: 106-7. PMID 15782171 DOI: 10.1038/Nmeth1104-106  0.762
2004 Vella MC, Reinert K, Slack FJ. Architecture of a validated microRNA::target interaction. Chemistry & Biology. 11: 1619-23. PMID 15610845 DOI: 10.1016/J.Chembiol.2004.09.010  0.742
2004 Vella MC, Choi EY, Lin SY, Reinert K, Slack FJ. The C. elegans microRNA let-7 binds to imperfect let-7 complementary sites from the lin-41 3'UTR. Genes & Development. 18: 132-7. PMID 14729570 DOI: 10.1101/Gad.1165404  0.751
2003 Johnson SM, Lin SY, Slack FJ. The time of appearance of the C. elegans let-7 microRNA is transcriptionally controlled utilizing a temporal regulatory element in its promoter. Developmental Biology. 259: 364-79. PMID 12871707 DOI: 10.1016/S0012-1606(03)00202-1  0.451
2003 Lin SY, Johnson SM, Abraham M, Vella MC, Pasquinelli A, Gamberi C, Gottlieb E, Slack FJ. The C elegans hunchback homolog, hbl-1, controls temporal patterning and is a probable microRNA target. Developmental Cell. 4: 639-50. PMID 12737800 DOI: 10.1016/S1534-5807(03)00124-2  0.754
2002 Ramaswamy G, Slack FJ. siRNA. A guide for RNA silencing. Chemistry & Biology. 9: 1053-5. PMID 12401489 DOI: 10.1016/S1074-5521(02)00249-1  0.3
2002 Banerjee D, Slack F. Control of developmental timing by small temporal RNAs: a paradigm for RNA-mediated regulation of gene expression. Bioessays : News and Reviews in Molecular, Cellular and Developmental Biology. 24: 119-29. PMID 11835276 DOI: 10.1002/Bies.10046  0.359
2002 Grosshans H, Slack FJ. Micro-RNAs: small is plentiful. The Journal of Cell Biology. 156: 17-21. PMID 11781331 DOI: 10.1083/Jcb.200111033  0.483
2000 Pasquinelli AE, Reinhart BJ, Slack F, Martindale MQ, Kuroda MI, Maller B, Hayward DC, Ball EE, Degnan B, Müller P, Spring J, Srinivasan A, Fishman M, Finnerty J, Corbo J, et al. Conservation of the sequence and temporal expression of let-7 heterochronic regulatory RNA. Nature. 408: 86-9. PMID 11081512 DOI: 10.1038/35040556  0.557
2000 Slack FJ, Basson M, Liu Z, Ambros V, Horvitz HR, Ruvkun G. The lin-41 RBCC gene acts in the C. elegans heterochronic pathway between the let-7 regulatory RNA and the LIN-29 transcription factor. Molecular Cell. 5: 659-69. PMID 10882102 DOI: 10.1016/S1097-2765(00)80245-2  0.689
2000 Reinhart BJ, Slack FJ, Basson M, Pasquinelli AE, Bettinger JC, Rougvie AE, Horvitz HR, Ruvkun G. The 21-nucleotide let-7 RNA regulates developmental timing in Caenorhabditis elegans. Nature. 403: 901-6. PMID 10706289 DOI: 10.1038/35002607  0.684
1999 Miyabayashi T, Palfreyman MT, Sluder AE, Slack F, Sengupta P. Expression and function of members of a divergent nuclear receptor family in Caenorhabditis elegans Developmental Biology. 215: 314-331. PMID 10545240 DOI: 10.1006/Dbio.1999.9470  0.324
1998 Slack F, Ruvkun G. Heterochronic genes in development and evolution. The Biological Bulletin. 195: 375-6. PMID 9924779 DOI: 10.2307/1543152  0.55
1998 Slack FJ, Ruvkun G. A novel repeat domain that is often associated with RING finger and B-box motifs. Trends in Biochemical Sciences. 23: 474-5. PMID 9868369 DOI: 10.1016/S0968-0004(98)01299-7  0.485
1997 Slack F, Ruvkun G. Temporal pattern formation by heterochronic genes. Annual Review of Genetics. 31: 611-34. PMID 9442909 DOI: 10.1146/Annurev.Genet.31.1.611  0.562
1995 Slack FJ, Serror P, Joyce E, Sonenshein AL. A gene required for nutritional repression of the Bacillus subtilis dipeptide permease operon Molecular Microbiology. 15: 689-702. PMID 7783641 DOI: 10.1111/J.1365-2958.1995.Tb02378.X  0.537
1993 Slack FJ, Mueller JP, Sonenshein AL. Mutations that relieve nutritional repression of the Bacillus subtilis dipeptide permease operon Journal of Bacteriology. 175: 4605-4614. PMID 8335620 DOI: 10.1128/Jb.175.15.4605-4614.1993  0.549
1991 Mueller JP, Mathiopoulos C, Slack FJ, Sonenshein AL. Identification of Bacillus subtilis adaptive response genes by subtractive differential hybridization Research in Microbiology. 142: 805-813. PMID 1784820 DOI: 10.1016/0923-2508(91)90059-J  0.555
1991 Slack FJ, Mueller JP, Strauch MA, Mathiopoulos C, Sonenshein AL. Transcriptional regulation of a Bacillus subtilis dipeptide transport operon Molecular Microbiology. 5: 1915-1925. PMID 1766371 DOI: 10.1111/J.1365-2958.1991.Tb00815.X  0.573
1991 Mathiopoulos C, Mueller JP, Slack FJ, Murphy CG, Patankar S, Bukusoglu G, Sonenshein AL. A Bacillus subtilis dipeptide transport system expressed early during sporulation Molecular Microbiology. 5: 1903-1913. PMID 1766370 DOI: 10.1111/J.1365-2958.1991.Tb00814.X  0.521
Show low-probability matches.